JAVELIN: avelumab another spear to fight urothelial carcinoma
Menée à partir des données de deux cohortes d'un essai de phase I incluant 249 patients atteints d'un carcinome urothélial de stade métastatique, cette étude évalue l'activité anti-tumorale, l'efficacité, du point de vue du taux de réponse globale, et la toxicité de l'avélumab, un anticorps anti-PD-L1, après l'échec d'un ou de plusieurs traitements à base de sels de platine (durée médiane de suivi : 9,9 mois)
Single-agent immune checkpoint blockers targeting programmed death-1 receptor (PD-1) or its ligand PD-L1 have rapidly become standard treatment options for patients with advanced urothelial carcinoma after progression on platinum-based chemotherapy, and are evolving as a first-line option for platinum-ineligible patients.1–4 Although the proportion of patients achieving a response in the second-line setting is only 15–25%, these responses are generally durable in conjunction with a favorable toxicity profile, which has led to substantial momentum to transition to an immunotherapy-based treatment approach from a chemotherapy-based approach for all settings.
The Lancet Oncology , commentaire, 2016